Erratum to: Biol Ther 4(1–2) (2014) DOI 10.1007/s13554-014-0017-1
The authors of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following corrections.
On pages 5 and 6, Table 1 will include a footnote for the prior non-Omnitrope rhGH therapy: “These patients are not mutually exclusive, they could have been on multiple GH therapies prior to switching to Omnitrope”.
On page 10 under the heading Discussion the recommended dose of GH therapy in TS patients pre- and post-switch should be 0.33 mg/kg/week. The sentence should now read “We recognize that the GH therapy dose that was used in TS patients pre- and post-switch was less than the recommended dose of 0.33 mg/kg/week”.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s13554-014-0017-1.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Rashid, N., Saenger, P., Wu, YL. et al. Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. Biol Ther 4, 81 (2014). https://doi.org/10.1007/s13554-014-0020-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13554-014-0020-6